New eczema drug IBI3033 enters first human tests
NCT ID NCT07549984
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental drug called IBI3033 in 16 adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body processes it. Participants will receive either IBI3033 or a placebo injection over 12 weeks, with follow-up for 4 more weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI3033 (an experimental drug given as an injection under the skin)
- What this could lead to
- If successful, this early study could pave the way for a new treatment option to ease symptoms of moderate-to-severe eczema.
- What could go wrong
- This is a very small, early-stage (Phase 1) trial focused on safety, not effectiveness. The drug may not work or could have side effects. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hangzhou First People's Hospital
Hangzhou, Hangzhou, 310006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?
- Can Real-World data unlock better skin disease care?
- Can a meditation app soothe teen eczema?